RUP: repeat-use procedure
A repeat-use procedure (RUP) is a further mutual recognition wave that adds new concerned member states to a product already authorised by DCP or MRP.
The repeat-use procedure has no separate legal text. It is the mutual recognition procedure of Article 28(2) of Directive 2001/83/EC used again after a first decentralised or mutual recognition procedure has closed, to extend the authorisation to Member States that were not in the original wave. The reference member state stays the same, updates its assessment report to reflect everything that has changed since the first procedure, and the new concerned member states recognise it. The CMDh publishes a best practice guide on repeat use that sets out the expectations.
Preparation matters more than the procedure itself. All pending variations must be finalised before the repeat-use procedure starts, so the dossier the new countries receive is the current approved one. The product information must already be harmonised across the existing Member States, and the dossier must be in eCTD with the full lifecycle visible to the reference member state. Each new concerned member state will also want its national requirements met: translations, mock-ups, local representative details and any national labelling text.
What goes wrong: starting a wave while a Type II variation is still open, which forces a wait or a withdrawal; a reference member state that has little capacity and offers a slot months away; national texts that differ from the common product information because earlier national variations were never aligned; and underestimating the national phase, when translations have to be approved and fees paid in each new country before marketing can begin. A new concerned member state can also raise questions on parts of the dossier that the original wave accepted years earlier, for example an outdated bioequivalence comparator or a manufacturing site whose GMP certificate has lapsed, and the applicant must answer within the standard timetable.
Companies sometimes change the reference member state before a repeat-use wave, for example when the original one has left the business or lost capacity. That is possible but needs the agreement of all authorities involved and adds time. Where many markets remain, a single large wave is usually cheaper than several small ones, because each wave carries its own reference member state fee and procedural overhead.
Timing
The reference member state has 90 days from a valid request to update its assessment report. The recognition phase then follows the standard mutual recognition timetable: Day 0 start, comments from the new concerned member states by Day 50, applicant responses, and closure by Day 90 if all agree. Disagreements on potential serious risk to public health go to the CMDh for 60 days under Article 29. National authorisations follow within 30 days of closure, subject to translations and fees in each country.
Used in
When planning the next markets, calculate the reference member state and concerned member state fees for a repeat-use wave with the Regunaut fee calculator.
Related terms
- MRP: mutual recognition procedureThe mutual recognition procedure (MRP) extends a national marketing authorisation from one EU/EEA Member State to others, which recognise it.
- DCP: decentralised procedureThe decentralised procedure (DCP) authorises a medicine in several EU/EEA Member States at once when it is not yet authorised in any of them.
- RMS: reference member stateThe reference member state (RMS) is the EU/EEA Member State that leads the assessment in a decentralised or mutual recognition procedure.
- CMS: concerned member stateA concerned member state (CMS) is any EU/EEA Member State, other than the reference member state, where an applicant seeks authorisation via a DCP or MRP.
- CMDh: Co-ordination Group for Mutual Recognition and Decentralised ProceduresThe CMDh is the group of national authority representatives that resolves disagreements in MRP and DCP and coordinates nationally authorised medicines.
Last updated